Copyright Seeking Alpha
Sangamo targets Q1 2026 BLA submission for Fabry gene therapy as FDA affirms accelerated pathway Nov. 06, 2025 11:56 PM ETSangamo Therapeutics, Inc. (SGMO) StockAI-Generated Earnings Calls Insights Comments Earnings Call Insights: Sangamo Therapeutics (SGMO) Q3 2025 Management View CEO Alexander Macrae highlighted continued advancement of the clinical and preclinical pipeline, with a focus on managing cash resources. Macrae stated, "In September, we presented promising detailed clinical data from our registrational STAAR study Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Quick Insights FDA reaffirmation supports ST-920's use of eGFR for accelerated approval, enabling a planned BLA submission as early as the first quarter of 2026. Current cash and equivalents, including recent Pfizer fees and stock sales, are expected to fund operations into the first quarter of 2026. Business development talks are advancing, aided by regulatory clarity, and the company is actively seeking additional non-dilutive capital and partnerships as a top priority. Recommended For You More Trending News
